Last reviewed · How we verify
Gastrografin
At a glance
| Generic name | Gastrografin |
|---|---|
| Also known as | Diatrizoate Meglumine, Diatrizoate Sodium, NDA-011245, Diatrizoate Meglumine, Diatrizoate Sodium |
| Sponsor | Nadja Haiden,MD |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Hypersensitivity or anaphylactoid reactions
- Edema of the face and glottis
- Respiratory distress
- Convulsions
- Shock
- Hematuria
- Perforation of the urethra or bladder
- Introduction of infection into the genitourinary tract
- Oliguria or anuria
- Hypothyroidism
- Transient thyroid suppression
Key clinical trials
- A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction (NA)
- Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction
- Optimizing Treatment of Adhesive Small Bowel Obstruction (PHASE3)
- Fluorescence Cholangiography During Cholecystectomy - a RCT (NA)
- Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure (PHASE3)
- Gastrografin for Treating Small Bowel Obstruction in Children (PHASE2, PHASE3)
- The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients. (PHASE4)
- Serum Thyroid Function After Iodinated Contrast Administration
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gastrografin CI brief — competitive landscape report
- Gastrografin updates RSS · CI watch RSS
- Nadja Haiden,MD portfolio CI